| Name | Title | Contact Details |
|---|---|---|
Felipe Baytelman |
Chief Technology Officer | Profile |
Planned Parenthood North Central States (PPNCS) and its subsidiary organizations provide, promote, and protect reproductive and sexual health through high quality care, education and advocacy. A member of America`s most trusted reproductive health care provider, our affiliate is proud to support and operate 29 health centers across our five-state region (Iowa, Minnesota, Nebraska, North Dakota and South Dakota). Each year, we provide health care to nearly 115,000 people and health education to more than 99,000 people in our region.
CliniComp is a global provider of Electronic Health Record (EHR) software and solutions that has enjoyed an unrivaled track record of performance and reliability in the most complex high acuity hospital environments for decades. Starting in 2014 CliniComp EHR extends the scope of coverage to Outpatient and Ancillaries such as Pharmacy, Radiology, and clinical laboratory information systems. This fully-integrated one stop expanded offering guarantees seamless CPOE and order/results management as well as transparent patient record viewing across all patient environments, distinct sites and time. Every Patient. Everywhere. For Life. The CCI system is certified for Stage 2 Meaningful Use and is currently supported internationally.
Teresian House is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Association for Laboratory Automation is a Geneva, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.